We are live on ! Find out more
ARKG icon

ARK Genomic Revolution ETF

233 hedge funds and large institutions have $614M invested in ARK Genomic Revolution ETF in 2025 Q3 according to their latest regulatory filings, with 42 funds opening new positions, 53 increasing their positions, 62 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 42 | Existing positions closed: 21

16% more capital invested

Capital invested by funds: $528M → $614M (+$85.7M)

8% more funds holding

Funds holding: 215233 (+18)

4.85% more ownership

Funds ownership: 49.93%54.79% (+4.9%)

10% less call options, than puts

Call options by funds: $78.8M | Put options by funds: $87.2M

15% less repeat investments, than reductions

Existing positions increased: 53 | Existing positions reduced: 62

Holders
233
Holders Change
+18
Holders Change %
+8.37%
% of All Funds
3.05%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
42
Increased
53
Reduced
62
Closed
21
Calls
$78.8M
Puts
$87.2M
Net Calls
-$8.44M
Net Calls Change
-$159K

ARKG Hedge Fund Activity: Q3 2025 in Review

233 of the 7,640 institutional investors tracked by Wall St. Rank reported a position in ARK Genomic Revolution ETF (ARKG) for Q3 2025, worth a combined $614M — up 16% from $528M a quarter earlier.

Buyers outnumbered sellers: 42 funds opened new ARKG positions and 21 closed out — a net gain of 21 holders — while 53 added to existing stakes and 62 trimmed.

The largest buyer was Citigroup, adding an estimated $21.4M. The largest seller was Goldman Sachs, cutting an estimated $25.9M.

  • 233 institutional investors held ARK Genomic Revolution ETF (ARKG) as of Q3 2025, up from 215 in Q2 2025.
  • Funds reported $614M of ARK Genomic Revolution ETF stock for Q3 2025, up 16% quarter-over-quarter.
  • 42 funds opened new ARK Genomic Revolution ETF positions in Q3 2025 and 21 closed out, a net change of +21 holders.
  • The largest ARK Genomic Revolution ETF buyer in Q3 2025 was Citigroup, an estimated $21.4M added.
  • The largest ARK Genomic Revolution ETF seller in Q3 2025 was Goldman Sachs, an estimated $25.9M sold.

Based on aggregated 13F filings for Q3 2025.